Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
Status:
Not yet recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
The goal of this Phase 2 trial is to evaluate a neoadjuvant treatment mode for locally
advanced rectal cancer (LARC), consisting of radiotherapy and concurrent
Trifluridine/Tipiracil (TAS-102). The main questions it aims to answer are: (i) whether
TAS-102 is effective in treating LARC, when combined with radiotherapy; (ii) whether TAS-102
is safe in combination with radiotherapy. Participants will receive one cycle of TAS-102
chemotherapy and neoadjuvant radiotherapy based on intensity-modulated technique. Then the
ones with a possibility of R0 resection will receive radical surgery followed by 6 cycles of
adjuvant XELOX (capecitabine plus oxaliplatin) chemotherapy.